Novo Nordisk, Eli Lilly & Co. and Sanofi dominate the market for insulin products worldwide, while the much-smaller Biocon is a key player in the copycat segment. The global insulin-pen market is ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.

At the time, the NYT noted that no other company had bid on the contract, which covered supply of 14 million pens for three years at roughly $2 per device. Novo had been supplying insulin pens to ...

Novo Nordisk announced plans Tuesday to lower the cost of several of its insulin products by up to 75% for people living with Type 1 and Type 2 diabetes.

Doctors Without Borders (MSF) isMSF has identified price as a barrier to the use of insulin pens in LMICs. The nonprofit published a paper on insulin pen prices in March, in which it said the ...

Novo Nordisk said on Wednesday it would discontinue its long-acting insulin Levemir in the United States, citing manufacturing constraints, reduced patient access and available alternatives.

Novo Nordisk is also discontinuing two insulin detemir solutions — Levemir Flexpen subcutaneous injection, 100 units per milliliter pen; and Levemir subcutaneous injection, 100 units per ...

The federal Inflation Reduction Act caps insulin costs at $35 a month for Medicare enrollees on Part D plans. Some insulin prices have more than tripled in the last two decades. About 37.3 million ...

Novo Nordisk A/S has entered into exclusive negotiations for a controlling stake in Biocorp SA, suppliers of Mallya, a Bluetooth-enabled smart add-on device for insulin pen injectors. The takeover ...

LONDON (CBS.MW) -- Technip on Tuesday said it won a 128 million euro contract to build an insulin plant in France for Novo Nordisk .